1. A method of preventing tumor progression in humans, comprising administering for more than 3 days a composition comprising CRF in a total daily dose exceeding 2 mg to a person potentially having a tumor. ! 2. A method of preventing tumor progression in humans, comprising administering a composition comprising CRF for more than 3 days, wherein CRF is administered at a dose effective to inhibit tumor progression to a person potentially having a tumor. ! 3. The method according to claim 1 or 2, where the composition is administered periodically. ! 4. The method according to claim 1 or 2, where the composition is administered for more than 5 days. ! 5. The method according to claim 4, where the composition is administered periodically. ! 6. The method according to claim 1 or 2, where the composition is administered for more than 7-14 days. ! 7. The method according to claim 6, where the composition is administered periodically. ! 8. The method according to claim 1 or 2, where the specified method further includes monitoring the progression of the tumor in humans. ! 9. The method according to claim 1 or 2, where the tumor is a brain tumor. ! 10. The method according to claim 9, where the brain tumor is glioblastoma, glioma, ependymoma, astrocytoma, medulloblastoma, neuroglioma, oligodendroglioma or meningioma. ! 11. The method according to claim 9, where the brain tumor is a secondary brain tumor or brain metastasis. ! 12. The method according to claim 1 or 2, where the composition comprises CRF conjugated to a biocompatible polymer. ! 13. The method of claim 12, wherein the composition comprises a CRF PEG conjugate. ! 14. The method according to claim 1, where the total daily dose of CRF is in the range from 2.5 mg to 20 mg. ! 15. The method according to 14, where the total daily dose of CRF is in the range from 4 mg to 10 mg. ! 16. The method according to any one of claims 1, 2, 14 or 15, where the composition is administered subcutaneously. ! 17. The method accordi
